Cargando…

Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments

BACKGROUND: To evaluate the benefits of SARS-CoV-2 vaccination in cancer patients it is relevant to understand the adaptive immune response elicited after vaccination. Patients affected by hematologic malignancies are frequently immune-compromised and show a decreased seroconversion rate compared to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfannes, Roald, Pierzchalski, Arkadiusz, Maddalon, Ambra, Simion, Alexandra, Zouboulis, Christos C., Behre, Gerhard, Zenclussen, Ana Claudia, Westphal, Sabine, Fest, Stefan, Herberth, Gunda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177659/ https://www.ncbi.nlm.nih.gov/pubmed/37187728 http://dx.doi.org/10.3389/fimmu.2023.1087996

Ejemplares similares

EpiVisR: exploratory data analysis and visualization in epigenome-wide association analyses
por: Röder, Stefan, et al.
Publicado: (2022)

Bisphenols, but not phthalate esters, modulate gene expression in activated human MAIT cells in vitro
por: Krause, J.L., et al.
Publicado: (2023)

Neoantigens in Hematologic Malignancies
por: Biernacki, Melinda A., et al.
Publicado: (2020)

Direct Effects of Glyphosate on In Vitro T Helper Cell Differentiation and Cytokine Production
por: Maddalon, Ambra, et al.
Publicado: (2022)

Radiotheranostic Agents in Hematological Malignancies
por: Caers, Jo, et al.
Publicado: (2022)

The Activation of Mucosal-Associated Invariant T (MAIT) Cells Is Affected by Microbial Diversity and Riboflavin Utilization in vitro
por: Krause, Jannike L., et al.
Publicado: (2020)

Natural Killer Cells Modulation in Hematological Malignancies
por: Baier, Céline, et al.
Publicado: (2013)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Maternal stress, child behavior and the promotive role of older siblings
por: Amici, Federica, et al.
Publicado: (2022)

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
por: Klausen, Uffe, et al.
Publicado: (2018)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Primary Immunodeficiencies and Hematologic Malignancies: A Diagnostic Approach
por: Chandra, Sharat, et al.
Publicado: (2022)

The role of interleukin-15 in the development and treatment of hematological malignancies
por: Sindaco, Paola, et al.
Publicado: (2023)

Elevated Gestational IL-13 During Fetal Development Is Associated With Hyperactivity and Inattention in Eight-Year-Old Children
por: Thürmann, Loreen, et al.
Publicado: (2019)

T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies
por: Janelle, Valérie, et al.
Publicado: (2020)

Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies
por: Mancini, Stéphane J.C., et al.
Publicado: (2021)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

An "unexpected" role for EMT transcription factors in hematological development and malignancy
por: Radhakrishnan, Karthika, et al.
Publicado: (2023)

Trends in mortality from infection among patients with hematologic malignancies: differences according to hematologic malignancy subtype
por: Yin, Xuejiao, et al.
Publicado: (2023)

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies
por: Gismondi, Angela, et al.
Publicado: (2015)

Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy
por: Sánchez-Ramón, Silvia, et al.
Publicado: (2016)

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2018)

Extracellular vesicles in hematological malignancies: EV-dence for reshaping the tumoral microenvironment
por: Van Morckhoven, David, et al.
Publicado: (2023)

Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
por: Tumino, Nicola, et al.
Publicado: (2021)

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
por: Allegra, Alessandro, et al.
Publicado: (2021)

A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies
por: Ramos-Mejia, Veronica, et al.
Publicado: (2022)

Cytokine Expression of Lung Bacterial Infection in Newly Diagnosed Adult Hematological Malignancies
por: Li, Zengzheng, et al.
Publicado: (2021)

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023)

Mucosal-associated invariant T cells in hematological malignancies: Current knowledge, pending questions
por: Treiner, Emmanuel
Publicado: (2023)

Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies
por: Cornel, Annelisa M., et al.
Publicado: (2018)

How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application
por: Luo, Shanshan, et al.
Publicado: (2020)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

Secondary Immune Deficiency and Primary Immune Deficiency Crossovers: Hematological Malignancies and Autoimmune Diseases
por: Ballow, Mark, et al.
Publicado: (2022)

Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing
por: Zhang, Tingting, et al.
Publicado: (2022)

Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
por: Lang, Yue, et al.
Publicado: (2023)

Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
por: Pittari, Gianfranco, et al.
Publicado: (2015)

Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies
por: Zaghi, Elisa, et al.
Publicado: (2019)

Abnormal microRNA expression in the course of hematological malignancies
por: Szymczyk, Agnieszka, et al.
Publicado: (2018)

Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy
por: Gies, Vincent, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq2bbkfl675kpvf8pil9adrrfa